VIR-7831 (GSK4182136) | COMET-ICE
Stage (next event)
Phase 2/3 (Data)
Catalyst Info & Data Links
TITLE: VIR-7831 in COVID - Phase 2/3 (Data)
ClinicalTrial.gov (NCT04545060): VIR-7831 for the Early Treatment of COVID-19 in Outpatients (COMET-ICE)
WHAT IS THE CATALYST EVENT?
WHEN WILL THE EVENT (OR DID THE EVENT) OCCUR?
End of the Year 2020
2020: A perspective on potential antibody-dependent enhancement of SARS-CoV-2. Nature, 1-14.
2020: Cross-neutralization of SARS-CoV-2 by a human monoclonal SARS-CoV antibody. Nature, 1-6.
Mechanism of Action
MECHANISM OF ACTION / RATIONALE
VIR-7831 is a monoclonal antibody that has demonstrated the ability to neutralize SARS-CoV-2 live virus in vitro. The antibody binds to an epitope on SARS-CoV-2 that is shared with SARS-CoV-1 (also known as SARS), indicating that the epitope is highly conserved, which may make it more difficult for escape mutants to develop. VIR-7831 has been engineered to enhance bioavailability and have an extended half-life.
Updated by HC
Prior Data (click to view full image)
Trial Design / Revenue (click to view full image)
See what the community is saying - click to see full post